Carroll Financial Associates’s VanEck Biotech ETF BBH Stock Holding History

Carroll Financial Associates’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$14K	Hold	76	–	–	﹤0.01%	1067
2021 Q3	$15K	Hold	76	–	–	﹤0.01%	1064
2021 Q2	$15K	Hold	76	–	–	﹤0.01%	1157
2021 Q1	$13K	Hold	76	–	–	﹤0.01%	1136
2020 Q4	$12K	Hold	76	–	–	﹤0.01%	1051
2020 Q3	$12K	Hold	76	–	–	﹤0.01%	982
2020 Q2	$12K	Hold	76	–	–	﹤0.01%	983
2020 Q1	$9K	Hold	76	–	–	﹤0.01%	961
2019 Q4	$10K	Hold	76	–	–	﹤0.01%	1043
2019 Q3	$8K	Hold	76	–	–	﹤0.01%	1058
2019 Q2	$9K	Hold	76	–	–	﹤0.01%	1037
2019 Q1	$9K	Buy	+76	New	+$9.6K	﹤0.01%	961

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Carroll Financial Associates's BBH Position: Q4 2021 in Review

Carroll Financial Associates held its VanEck Biotech ETF (BBH) position steady in Q4 2021 at 76 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #1067.

Carroll Financial Associates first reported a position in BBH in Q1 2019 and has held it in 12 quarters since. The position peaked at $15K in Q3 2021. 126 funds tracked by Wall St. Rank hold BBH as of Q4 2021.

Carroll Financial Associates held 76 shares of VanEck Biotech ETF worth $14K as of Q4 2021.
Carroll Financial Associates left its VanEck Biotech ETF share count unchanged in Q4 2021.
VanEck Biotech ETF made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1067 holding.
Carroll Financial Associates first reported a position in VanEck Biotech ETF in Q1 2019 and has held it in 12 quarters since.
Carroll Financial Associates's VanEck Biotech ETF position peaked at $15K in Q3 2021.
126 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.